Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
M. Burnier, A. Zanchi.
Blockade of the renin-angiotensin-aldosterone system: a Key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
J Hypertens, (2006), 24 pp. 11-25
[2.]
G. Mancia.
The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.
Acta Diabetol, (2005), 42 pp. 17-25
[3.]
J.R. González Juanatey, P. Mazon Ramos, F. Sora Arcos, V. Barrios Alonso, L. Rodríguez Padial, V. Bertomeu Martinez.
Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en Hipertensión Arterial.
Rev Esp Cardiol, (2003), 56 pp. 487-497
[4.]
2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension J Hypertens. 2003;21:1011-53
[5.]
K. Teo, S. Yusuf, P. Sleight, C. Anderson, F. Mookadam, B. Ramos, et al.
Rationale design and base line characteristics of 2 large simple randomized trials evaluating telmisartan, ramipril, and their combination in high risk patients (ONTARGET/TRANSCEND).
Am Heart J, (2004), 148 pp. 52-61
[6.]
J. Cosin Aguilar, A. Hernadiz, R. Aristegui.
Estudio CORONARIA. Riesgo coronario y y prevalencia de cardiopatías en pacientes hipertensos con afectación renal en asistencia primaria.
Rev Esp Cardiol, (2006), 59 pp. 1026-1032
[7.]
J.P. Casas, W. Cha, S. Loukogeorgakis, P. Vallance, L. Smeeth, A.D. Hingorani, et al.
Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis.
Lancet, (2005), 366 pp. 2026-2033
[8.]
Effect of ramipril in reducing sudden.
deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Circulation, (2004), 110 pp. 1413-1417
[9.]
S. Ljungman, J. Kjekshus, K. Swedberg.
Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial).
Am J Cardiol, (1992), 70 pp. 479-487
[10.]
E.L. Knight, R.J. Glynn, K.M. McIntyre, H. Mogun, J. Avorn.
Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Am Heart J, (1999), 138 pp. 849-855
[11.]
M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr, T.E. Cuddy, et al.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
N Engl J Med, (1992), 327 pp. 669-677
[12.]
Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
Lancet, (1993), 342 pp. 821-828
[13.]
C. Trop Pederse, L. Kobert.
Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril cardiac evaluation.
Lancet, (1999), 354 pp. 9-12
[14.]
E. Ambrosine, C. Borghi, C. Magnani.
The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.
N Engl J Med, (1995), 332 pp. 80-85
[15.]
M.A. Konstam, J.D. Neaton, P.A. Pole-Wilson, P. Pitt, R. Segal, D. Sharma, et al.
Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II).
Am Heart J, (2005), 150 pp. 123-131
[16.]
S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, et al.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Lancet, (2004), 363 pp. 2022-2031
[17.]
E. Fossum, A. Moam, S.E. Kejeldense.
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
J Am Coll Cardiol, (2005), 46 pp. 770-775
[18.]
L.H. Lindholm, H. Ibsen, B. Dlof, R.B. Devereux, G. Beevers, U. de Faire, et al.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet, (2002), 359 pp. 1004-1010
[19.]
Stroke prevention with the angiotensin.
II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
J Am Coll Cardiol, (2004), 44 pp. 1175-1180
[20.]
S.D. Solomon, D. Wang, P. Fin, H. Skali, L. Zornoff, J.J.V. McMurray, et al.
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation, (2004), 110 pp. 2180-2183
[21.]
G.L. Bakris, M.R. Weir, M.S. Shanifar, Z. Zhang, J. Douglas, D.J. Van Dijk, et al.
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Arch Intern Med, (2003), 163 pp. 1555-1565
[22.]
H.D. White, P. Aylward, Z. Huamg, A.J. Dalby, W.D. Weaver, S. Barvik, et al.
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Circulation, (2005), 112 pp. 3391-3399
[23.]
L.G. Hunsiker.
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
J Manag Care Pharm, (2004), 10 pp. 12-17
[24.]
C.E. Mogensen, S. Neldam, I. Tikkanen, S. Oren.
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
BMJ, (2000), 321 pp. 1440-1444
[25.]
J.J. MacMurray, J. Ostergreen, K. Sedwerg, C.B. Granger, P. Held, E.L. Michelson, et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet, (2003), 362 pp. 767-771
Full English text available at: www.revespcardiol.org
Copyright ©
2007. Sociedad Española de Cardiología